Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis.
Objective: The objective of this work is to perform a systematic review and meta-analysis of all randomized controlled trials comparing a single intravenous dose of palonosetron (PAL) 0.25 mg with other 5-HT(3)R in patients receiving moderately or highly emetogenic (MoHE) chemotherapy.Methods: Sever...
| Publicado en: | Supportive Care in Cancer Vol. 19; no. 6; pp. 823 - 833 |
|---|---|
| Autores principales: | , , , , , , , , , , , |
| Formato: | research Journal Article |
| Publicado: |
Springer Nature
Jun2011
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104890663&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 104890663 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 09414355 O1J jtl: Supportive Care in Cancer issn: 09414355 maglogo: N pubinfo: dt: Jun2011 vid: 19 iid: 6 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 104890663 60279852 NLM20495832 2011040078 10.1007/s00520-010-0908-8 NLM20495832 104890663 ppf: 823 ppct: 10 formats: fmt: @attributes: type: P tig: atl: Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. aug: au: Botrel TE Clark OA Clark L Paladini L Faleiros E Pegoretti B Botrel, Tobias Engel Ayer Clark, Otávio Augusto C Clark, Luciana Paladini, Luciano Faleiros, Enéas Pegoretti, Bruna affil: Rua Tranquillo Prosperi, 143, Campinas, São Paulo, 13084-778, Brazil sug: subj: Antiemetics Therapeutic Use Isoquinolines Therapeutic Use Heterocyclic Compounds Therapeutic Use Vomiting Prevention and Control Antiemetics Adverse Effects Antiemetics Pharmacodynamics Antineoplastic Agents Adverse Effects Antineoplastic Agents Therapeutic Use Glucocorticoids Therapeutic Use Human Isoquinolines Adverse Effects Isoquinolines Pharmacodynamics Nausea Chemically Induced Nausea Prevention and Control Neoplasms Drug Therapy Heterocyclic Compounds Adverse Effects Heterocyclic Compounds Pharmacodynamics Serotonin Antagonists Adverse Effects Serotonin Antagonists Pharmacodynamics Serotonin Antagonists Therapeutic Use Vomiting Chemically Induced ab: Objective: The objective of this work is to perform a systematic review and meta-analysis of all randomized controlled trials comparing a single intravenous dose of palonosetron (PAL) 0.25 mg with other 5-HT(3)R in patients receiving moderately or highly emetogenic (MoHE) chemotherapy.Methods: Several databases were searched, including MEDLINE, EMBASE, LILACS, and CENTRAL. The primary endpoints were the incidence of acute and delayed nausea and vomiting. The side effects of each treatment were analyzed. A subgroup analysis was performed to evaluate the influence of the use of corticosteroids. The results are expressed as risk ratio (RR) and the correspondent 95% confidence interval (CI).Results: Five studies were included, with 2057 patients. PAL was compared with ondansetron, granisetron, and dolasetron. Patients in PAL group had less nausea, both acute (RR = 0.86; CI 95% = 0.76 to 0.96; p = 0.007) and delayed (RR = 0.82; CI95% = 0.75 to 0.89; p < 0.00001). They also had less acute vomiting (RR = 0.76; CI 95% = 0.66 to 0.88; p = 0.0002) and delayed vomiting (RR = 0.76; CI95% = 0.68 to 0.85; p < 0.00001). There were no statistical differences in side effects like headache (RR = 0.84; CI 95% = 0.61 to 1.17; p = 0.30), dizziness (RR = 0.40; CI 95% = 0.13 to 1.27; p = 0.12), constipation (RR = 1.29; CI 95% = 0.77 to 2.17; p = 0.33) or diarrhea (RR = 0.67; CI 95% = 0.24 to 1.85; p = 0.44). Patients receiving PAL presented less nausea and vomiting regardless of the use of corticoids. We found no statistical heterogeneity in the global analysis.Conclusion: PAL was more effective than the other 5-HT(3)R in preventing acute and delayed CINV in patients receiving MoHE treatments, regardless of the use of concomitant corticosteroids. pubtype: Academic Journal doctype: research Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|